Cranofacial osteosarcoma

Single institutional experience in Korea

Seungtaek Lim, Soohyeon Lee, SunYoung Rha, Jae Kyung Rho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Craniofacial osteosarcoma is a rare disease accounting for only 1% of all head and neck malignancies. Its clinical features and optimal treatments are not yet clearly established. Methods: We retrospectively analyzed the clinical course of 15 patients with craniofacial osteosarcoma treated in a single institute. Results: Out of 13 patients who initially underwent primary mass resection, disease recurrence was found in five (36%). Patients with positive surgical margins showed higher recurrence and shorter median recurrence-free and overall survival. Of three patients who had secondary operation after local recurrence, two survived for 44.6 and 64.2 months, respectively. One patient who underwent repeated lung metastasectomy had a disease-free survival of 18.4 months from the first recurrence. Conclusion: The current study demonstrates that positive surgical margins are important predictive factors for recurrence and overall survival. Salvage surgery for local recurrence and metastasectomy for systemic recurrence might have a positive impact on survival.

Original languageEnglish
Pages (from-to)e149-e153
JournalAsia-Pacific Journal of Clinical Oncology
Volume12
Issue number1
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

Osteosarcoma
Korea
Recurrence
Metastasectomy
Survival
Rare Diseases
Disease-Free Survival
Neck
Head
Lung

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Lim, Seungtaek ; Lee, Soohyeon ; Rha, SunYoung ; Rho, Jae Kyung. / Cranofacial osteosarcoma : Single institutional experience in Korea. In: Asia-Pacific Journal of Clinical Oncology. 2016 ; Vol. 12, No. 1. pp. e149-e153.
@article{e2896762bc6742cd821909d718a4f0be,
title = "Cranofacial osteosarcoma: Single institutional experience in Korea",
abstract = "Introduction: Craniofacial osteosarcoma is a rare disease accounting for only 1{\%} of all head and neck malignancies. Its clinical features and optimal treatments are not yet clearly established. Methods: We retrospectively analyzed the clinical course of 15 patients with craniofacial osteosarcoma treated in a single institute. Results: Out of 13 patients who initially underwent primary mass resection, disease recurrence was found in five (36{\%}). Patients with positive surgical margins showed higher recurrence and shorter median recurrence-free and overall survival. Of three patients who had secondary operation after local recurrence, two survived for 44.6 and 64.2 months, respectively. One patient who underwent repeated lung metastasectomy had a disease-free survival of 18.4 months from the first recurrence. Conclusion: The current study demonstrates that positive surgical margins are important predictive factors for recurrence and overall survival. Salvage surgery for local recurrence and metastasectomy for systemic recurrence might have a positive impact on survival.",
author = "Seungtaek Lim and Soohyeon Lee and SunYoung Rha and Rho, {Jae Kyung}",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/ajco.12072",
language = "English",
volume = "12",
pages = "e149--e153",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "1",

}

Cranofacial osteosarcoma : Single institutional experience in Korea. / Lim, Seungtaek; Lee, Soohyeon; Rha, SunYoung; Rho, Jae Kyung.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 12, No. 1, 01.03.2016, p. e149-e153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cranofacial osteosarcoma

T2 - Single institutional experience in Korea

AU - Lim, Seungtaek

AU - Lee, Soohyeon

AU - Rha, SunYoung

AU - Rho, Jae Kyung

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Introduction: Craniofacial osteosarcoma is a rare disease accounting for only 1% of all head and neck malignancies. Its clinical features and optimal treatments are not yet clearly established. Methods: We retrospectively analyzed the clinical course of 15 patients with craniofacial osteosarcoma treated in a single institute. Results: Out of 13 patients who initially underwent primary mass resection, disease recurrence was found in five (36%). Patients with positive surgical margins showed higher recurrence and shorter median recurrence-free and overall survival. Of three patients who had secondary operation after local recurrence, two survived for 44.6 and 64.2 months, respectively. One patient who underwent repeated lung metastasectomy had a disease-free survival of 18.4 months from the first recurrence. Conclusion: The current study demonstrates that positive surgical margins are important predictive factors for recurrence and overall survival. Salvage surgery for local recurrence and metastasectomy for systemic recurrence might have a positive impact on survival.

AB - Introduction: Craniofacial osteosarcoma is a rare disease accounting for only 1% of all head and neck malignancies. Its clinical features and optimal treatments are not yet clearly established. Methods: We retrospectively analyzed the clinical course of 15 patients with craniofacial osteosarcoma treated in a single institute. Results: Out of 13 patients who initially underwent primary mass resection, disease recurrence was found in five (36%). Patients with positive surgical margins showed higher recurrence and shorter median recurrence-free and overall survival. Of three patients who had secondary operation after local recurrence, two survived for 44.6 and 64.2 months, respectively. One patient who underwent repeated lung metastasectomy had a disease-free survival of 18.4 months from the first recurrence. Conclusion: The current study demonstrates that positive surgical margins are important predictive factors for recurrence and overall survival. Salvage surgery for local recurrence and metastasectomy for systemic recurrence might have a positive impact on survival.

UR - http://www.scopus.com/inward/record.url?scp=84973567196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973567196&partnerID=8YFLogxK

U2 - 10.1111/ajco.12072

DO - 10.1111/ajco.12072

M3 - Article

VL - 12

SP - e149-e153

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 1

ER -